Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Celldex Therapeutics (CLDX) Cash from Financing Activities (2016 - 2025)

Historic Cash from Financing Activities for Celldex Therapeutics (CLDX) over the last 16 years, with Q3 2025 value amounting to $774000.0.

  • Celldex Therapeutics' Cash from Financing Activities fell 3753.03% to $774000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.4 million, marking a year-over-year decrease of 9978.36%. This contributed to the annual value of $441.4 million for FY2024, which is 10207.5% up from last year.
  • According to the latest figures from Q3 2025, Celldex Therapeutics' Cash from Financing Activities is $774000.0, which was down 3753.03% from $63000.0 recorded in Q2 2025.
  • In the past 5 years, Celldex Therapeutics' Cash from Financing Activities ranged from a high of $436.1 million in Q1 2024 and a low of -$25000.0 during Q2 2021
  • For the 5-year period, Celldex Therapeutics' Cash from Financing Activities averaged around $49.3 million, with its median value being $426000.0 (2021).
  • Per our database at Business Quant, Celldex Therapeutics' Cash from Financing Activities crashed by 10001.51% in 2021 and then skyrocketed by 6274034.58% in 2024.
  • Celldex Therapeutics' Cash from Financing Activities (Quarter) stood at $426000.0 in 2021, then soared by 227.46% to $1.4 million in 2022, then skyrocketed by 15482.37% to $217.4 million in 2023, then crashed by 99.82% to $386000.0 in 2024, then skyrocketed by 100.52% to $774000.0 in 2025.
  • Its Cash from Financing Activities was $774000.0 in Q3 2025, compared to $63000.0 in Q2 2025 and $202000.0 in Q1 2025.